1.jpg
4.jpg
2.jpg
3.jpg
5.jpg
6.jpg
7.jpg
    Pathways to Prevention: A Policy Discussion on Research & Treatments for Alzheimer’s   More than 5 million Americans currently suffer from Alzheimer’s and, in 2016, the disease will cost the U.S. healthcare system $236 billion. On Thursday, June 23, The Hill held a discussion on how policymakers and the healthcare industry can collaborate to find more effective treatments for Alzheimer’s. What developments and information are prompting breakthroughs in disease research? What are the potential pathways to meeting NIH’s 2025 prevention goal?    Featured speakers include:   SEN. SHELLEY MOORE CAPITO  (R-WV)  SEN. ED MARKEY  (D-MA)  JILL LESSER , President, WomenAgainstAlzheimer's Network  RONALD C. PETERSEN , Ph.D., M.D., Director, Mayo Alzheimer's Disease Research Center, Mayo Clinic College of Medicine  LORI REILLY , Executive Vice President for Policy and Research, PhRMA  LAURIE RYAN , Ph.D . , Chief, Dementias of Aging Branch & Program Director, Alzheimer's Disease Clinical Trials, National Institute on Aging, National Institutes of Health  DAVE RICKS , Senior Vice President & President of Lilly Bio-Medicines, Eli Lilly and Company  WILLIAM THIES , Ph.D., Senior Scientist in Residence, Alzheimer's Association   
1.jpg
4.jpg
2.jpg
3.jpg
5.jpg
6.jpg
7.jpg
    Pathways to Prevention: A Policy Discussion on Research & Treatments for Alzheimer’s   More than 5 million Americans currently suffer from Alzheimer’s and, in 2016, the disease will cost the U.S. healthcare system $236 billion. On Thursday, June 23, The Hill held a discussion on how policymakers and the healthcare industry can collaborate to find more effective treatments for Alzheimer’s. What developments and information are prompting breakthroughs in disease research? What are the potential pathways to meeting NIH’s 2025 prevention goal?    Featured speakers include:   SEN. SHELLEY MOORE CAPITO  (R-WV)  SEN. ED MARKEY  (D-MA)  JILL LESSER , President, WomenAgainstAlzheimer's Network  RONALD C. PETERSEN , Ph.D., M.D., Director, Mayo Alzheimer's Disease Research Center, Mayo Clinic College of Medicine  LORI REILLY , Executive Vice President for Policy and Research, PhRMA  LAURIE RYAN , Ph.D . , Chief, Dementias of Aging Branch & Program Director, Alzheimer's Disease Clinical Trials, National Institute on Aging, National Institutes of Health  DAVE RICKS , Senior Vice President & President of Lilly Bio-Medicines, Eli Lilly and Company  WILLIAM THIES , Ph.D., Senior Scientist in Residence, Alzheimer's Association   
 Pathways to Prevention: A Policy Discussion on Research & Treatments for Alzheimer’sMore than 5 million Americans currently suffer from Alzheimer’s and, in 2016, the disease will cost the U.S. healthcare system $236 billion. On Thursday, June 23, The Hill held a discussion on how policymakers and the healthcare industry can collaborate to find more effective treatments for Alzheimer’s. What developments and information are prompting breakthroughs in disease research? What are the potential pathways to meeting NIH’s 2025 prevention goal?Featured speakers include:SEN. SHELLEY MOORE CAPITO (R-WV)SEN. ED MARKEY (D-MA)JILL LESSER, President, WomenAgainstAlzheimer's NetworkRONALD C. PETERSEN, Ph.D., M.D., Director, Mayo Alzheimer's Disease Research Center, Mayo Clinic College of MedicineLORI REILLY, Executive Vice President for Policy and Research, PhRMALAURIE RYAN, Ph.D., Chief, Dementias of Aging Branch & Program Director, Alzheimer's Disease Clinical Trials, National Institute on Aging, National Institutes of HealthDAVE RICKS, Senior Vice President & President of Lilly Bio-Medicines, Eli Lilly and CompanyWILLIAM THIES, Ph.D., Senior Scientist in Residence, Alzheimer's Association 
info
prev / next